Literature DB >> 19654299

Nicotine stimulates PPARbeta/delta expression in human lung carcinoma cells through activation of PI3K/mTOR and suppression of AP-2alpha.

XiaoJuan Sun1, Jeffrey D Ritzenthaler, XiaoRong Zhong, Ying Zheng, Jesse Roman, ShouWei Han.   

Abstract

We previously showed that nicotine stimulates non-small cell lung carcinoma (NSCLC) cell proliferation through nicotinic acetylcholine receptor (nAChR)-mediated signals. Activation of peroxisome proliferator-activated receptor beta/delta (PPARbeta/delta) has also been shown to induce NSCLC cell growth. Here, we explore the potential link between nicotine and PPARbeta/delta and report that nicotine increases the expression of PPARbeta/delta protein; this effect was blocked by an alpha7 nAChR antagonist (alpha-bungarotoxin), by alpha7 nAChR short interfering RNA, and by inhibitors of phosphatidylinositol 3-kinase (PI3K; wortmannin and LY294002) and mammalian target of rapamycin (mTOR; rapamycin). In contrast, this effect was enhanced by PUN282987, an alpha7 nAChR agonist. Silencing of PPARbeta/delta attenuated the stimulatory effect of nicotine on cell growth, which was overcome by transfection of an exogenous PPARbeta/delta expression vector. Of note, nicotine induced complex formation between alpha7 nAChR and PPARbeta/delta protein and increased PPARbeta/delta gene promoter activity through inhibition of AP-2alpha as shown by reduced AP-2alpha binding using electrophoretic gel mobility shift and chromatin immunoprecipitation assays. In addition, silencing of Sp1 attenuated the effect of nicotine on PPARbeta/delta. Collectively, our results show that nicotine increases PPARbeta/delta gene expression through alpha7 nAChR-mediated activation of PI3K/mTOR signals that inhibit AP-2alpha protein expression and DNA binding activity to the PPARbeta/delta gene promoter. Sp1 seems to modulate this process. This study unveils a novel mechanism by which nicotine promotes human lung carcinoma cell growth.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19654299      PMCID: PMC2745317          DOI: 10.1158/0008-5472.CAN-09-1001

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  47 in total

1.  Isoform specific changes in PPAR alpha and beta in colon and breast cancer with differentiation.

Authors:  Cho S Aung; Helen M Faddy; Erin J Lister; Gregory R Monteith; Sarah J Roberts-Thomson
Journal:  Biochem Biophys Res Commun       Date:  2005-12-20       Impact factor: 3.575

Review 2.  The genetics of nicotine dependence.

Authors:  Ming D Li
Journal:  Curr Psychiatry Rep       Date:  2006-04       Impact factor: 5.285

Review 3.  Combined modality trials in unresectable stage III non-small cell lung cancer: the Cancer and Leukemia Group B experience.

Authors:  Mark A Socinski
Journal:  Semin Oncol       Date:  2005-04       Impact factor: 4.929

4.  Inhibition of Sp1 activity by a decoy PNA-DNA chimera prevents urokinase receptor expression and migration of breast cancer cells.

Authors:  Antonella Zannetti; Silvana Del Vecchio; Alessandra Romanelli; Stefania Scala; Michele Saviano; Gaetano Cali'; M Patrizia Stoppelli; Carlo Pedone; Marco Salvatore
Journal:  Biochem Pharmacol       Date:  2005-11-01       Impact factor: 5.858

5.  Transcriptional repression of peroxisome proliferator-activated receptor beta/delta in murine keratinocytes by CCAAT/enhancer-binding proteins.

Authors:  Nicolas Di-Poï; Béatrice Desvergne; Liliane Michalik; Walter Wahli
Journal:  J Biol Chem       Date:  2005-09-15       Impact factor: 5.157

6.  Peroxisome proliferator-activated receptor delta as a molecular target to regulate lung cancer cell growth.

Authors:  Keiko Fukumoto; Yoshihisa Yano; Nantiga Virgona; Hiromi Hagiwara; Hiromi Sato; Hironobu Senba; Kazuyuki Suzuki; Ryuji Asano; Kazuhiko Yamada; Tomohiro Yano
Journal:  FEBS Lett       Date:  2005-07-04       Impact factor: 4.124

Review 7.  The role of peroxisome proliferator-activated receptor-beta/delta in epithelial cell growth and differentiation.

Authors:  Andrew D Burdick; Dae J Kim; Marjorie A Peraza; Frank J Gonzalez; Jeffrey M Peters
Journal:  Cell Signal       Date:  2005-08-16       Impact factor: 4.315

Review 8.  PPAR gamma and human metabolic disease.

Authors:  Robert K Semple; V Krishna K Chatterjee; Stephen O'Rahilly
Journal:  J Clin Invest       Date:  2006-03       Impact factor: 14.808

9.  Ligand activation of peroxisome proliferator-activated receptor beta inhibits colon carcinogenesis.

Authors:  Holly E Marin; Marjorie A Peraza; Andrew N Billin; Timothy M Willson; Jerrold M Ward; Mary J Kennett; Frank J Gonzalez; Jeffrey M Peters
Journal:  Cancer Res       Date:  2006-04-15       Impact factor: 13.312

10.  PPARbeta/delta selectively induces differentiation and inhibits cell proliferation.

Authors:  D J Kim; M T Bility; A N Billin; T M Willson; F J Gonzalez; J M Peters
Journal:  Cell Death Differ       Date:  2006-01       Impact factor: 12.067

View more
  22 in total

1.  Transcriptional repression of the α7 nicotinic acetylcholine receptor subunit gene (CHRNA7) by activating protein-2α (AP-2α).

Authors:  Jessica Finlay-Schultz; Andrew Canastar; Margaret Short; Mohamed El Gazzar; Christina Coughlan; Sherry Leonard
Journal:  J Biol Chem       Date:  2011-10-06       Impact factor: 5.157

Review 2.  From smoking to lung cancer: the CHRNA5/A3/B4 connection.

Authors:  M R D Improgo; M D Scofield; A R Tapper; P D Gardner
Journal:  Oncogene       Date:  2010-06-28       Impact factor: 9.867

Review 3.  α7 nicotinic acetylcholine receptors in lung cancer.

Authors:  Shengchao Wang; Yue Hu
Journal:  Oncol Lett       Date:  2018-05-30       Impact factor: 2.967

Review 4.  Dissecting the role of peroxisome proliferator-activated receptor-β/δ (PPARβ/δ) in colon, breast, and lung carcinogenesis.

Authors:  Jeffrey M Peters; Jennifer E Foreman; Frank J Gonzalez
Journal:  Cancer Metastasis Rev       Date:  2011-12       Impact factor: 9.264

5.  Nicotine up-regulated 4-1BBL expression by activating Mek-PI3K pathway augments the efficacy of bone marrow-derived dendritic cell vaccination.

Authors:  Hao Jie Jin; Hua Xiu Sui; Yi Nan Wang; Feng Guang Gao
Journal:  J Clin Immunol       Date:  2012-08-17       Impact factor: 8.317

6.  Anticancer actions of PPARγ ligands: Current state and future perspectives in human lung cancer.

Authors:  Shou Wei Han; Jesse Roman
Journal:  World J Biol Chem       Date:  2010-03-26

7.  Mouse cardiac acyl coenzyme a synthetase 1 deficiency impairs Fatty Acid oxidation and induces cardiac hypertrophy.

Authors:  Jessica M Ellis; Shannon M Mentock; Michael A Depetrillo; Timothy R Koves; Shiraj Sen; Steven M Watkins; Deborah M Muoio; Gary W Cline; Heinrich Taegtmeyer; Gerald I Shulman; Monte S Willis; Rosalind A Coleman
Journal:  Mol Cell Biol       Date:  2011-01-18       Impact factor: 4.272

8.  Nicotine stimulated dendritic cells could achieve anti-tumor effects in mouse lung and liver cancer.

Authors:  Feng Guang Gao; Hai Tao Li; Zhi Jing Li; Jian Ren Gu
Journal:  J Clin Immunol       Date:  2010-10-19       Impact factor: 8.317

9.  Tolfenamic acid decreases c-Met expression through Sp proteins degradation and inhibits lung cancer cells growth and tumor formation in orthotopic mice.

Authors:  Jimmie Colon; Md Riyaz Basha; Rafael Madero-Visbal; Santhi Konduri; Cheryl H Baker; Luis J Herrera; Stephen Safe; David Sheikh-Hamad; Ala Abudayyeh; Beatrice Alvarado; Maen Abdelrahim
Journal:  Invest New Drugs       Date:  2009-10-23       Impact factor: 3.850

10.  Sp1 expression regulates lung tumor progression.

Authors:  T-I Hsu; M-C Wang; S-Y Chen; Y-M Yeh; W-C Su; W-C Chang; J-J Hung
Journal:  Oncogene       Date:  2011-12-12       Impact factor: 9.867

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.